BPC-157 is a research peptide and is not FDA-approved
S., Lund, A., Vilsboll, T., Knop, F
In reality, healing is complex
The salutary effect of BPC 157 therapy (10 ng and 10 g/kg in pretreatment and post-treatment regimens) was also observed in terms of mortality, which was significantly lower in BPC 157 groups (Table 3)
The two compounds target entirely different systems: Semax acts on neurotrophic factors and neurotransmitter signaling in the brain, while the Wolverine Blend acts on tissue repair and inflammation in the body
The peptide has since demonstrated remarkable healing properties across multiple organ systems and tissue types